Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 11/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531167 | 1.00 | TYMP (0.46) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL7261566 | 0.94 | TYMP (0.46) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL3065836 | 0.94 | TYMP (0.47) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL3065837 | 0.94 | TYMP (0.47) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL29254521 | 0.93 | TYMP (0.43) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL29254523 | 0.93 | TYMP (0.43) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL7917669 | 0.92 | TYMP (0.45) | TYMPP2RY6P2RY14NT5ETMIGD3 | |
| SCHEMBL3070612 | 0.91 | TYMP (0.54) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL3070618 | 0.91 | TYMP (0.54) | TYMPP2RY6ALDH1A1HTTP2RY14 | |
| SCHEMBL13714387 | 0.90 | TYMP (0.45) | TYMPP2RY6ALDH1A1HTTP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | FLAGSHIP PIONEERING, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250000890-A1 | TREM COMPOSITIONS AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2025-01-02 | — | — | US | disclosed |
| US-12121531-B2 | TREM compositions and uses thereof | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-10-22 | — | — | US | disclosed |
| WO-2024050267-A1 | OLIGONUCLEOTIDE DENDRON MOLECULAR VACCINES | NORTHWESTERN UNIVERSITY (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230167450-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023049816-A9 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-4138858-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | Flagship Pioneering, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4138857-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | Flagship Pioneering, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| US-5962672-A | OLIGONUCLEOTIDES AGAINST NUCLEIC ACID WHICH CODES FOR SMALL GUANOSINE TRIPHOSPHATASE IMPORTANT IN REGULATION OF CYTOSKELETON DURING CELL CYCLE; FOR ANTICARCINOGENIC/ANTITUMOR AGENTS | ISIS PHARMACEUTICALS INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5962671-A | OLIGONUCLEOTIDE WHICH SUPPRESSES GENE EXPRESSION OF FACTOR ASSOCIATED WITH NEUTRAL SPHINGOMYELINASE ACTIVATION; FACTOR IS IS A MEDIATOR OF TUMOR NECROSIS FACTOR ACTIVATION OF THAT ENZYME THROUGH A SIGNAL TRANSDUCTION PATHWAY; GENE THERAPY | ISIS PHARMACEUTICALS INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5958771-A | OLIGONUCLEOTIDE FROM 8 TO 30 NUCLEOTIDES IN LENGTH; FOR DIAGNOSIS AND THERAPY; ANTITUMOR/ANTIINFLAMMATORY AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5958772-A | TARGETS TO NUCLEIC ACID MOLECULE ENCODING HUMAN CELLULAR INHIBITORS OF APOTOPSIS-1 | ISIS PHARMACEUTICALS INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5959097-A | OLIGONUCLEOTIDE OF 8 TO 30 NUCLEOTIDES WHICH SUPPRESSES EXPRESSION OF SIGNAL TRANSDUCTION KINASE; FOR TREATMENT OF INFECTIONS; ANTIINFLAMMATORY/ANTITUMOR AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5958773-A | ANTISENSE COMPOUND 8 TO 30 NUCLEOTIDES IN LENGTH TARGETED TO A NUCLEIC ACID ENCODING HUMAN AKT-1, OF THE SERINE/THREONINE KINASE FAMILY INVOLVED IN SIGNALLING PATHWAYS; INHIBITING EXPRESSION OF AKT-1 WITH THE ANTISENSE COMPOUND | ISIS PHARMACEUTICALS INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5951455-A | OLIGONUCLEOTIDES, TARGETED TO NUCLEIC ACIDS WITH MODULATION AND EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5948680-A | ANTISENSE OLIGONUCLEOTIDE TARGETED TO NUCLEIC ACIDS ENCODING ELK-1; ANTIPROLIFERATIVE AGENTS | ISIS PHARMACEUTICALS INC. (US) | 1999-09-07 | — | — | US | disclosed |
| US-5945290-A | OLIGONUCLEOTIDES TARGETED AGAINST SPECIFIC NUCLEIC ACIDS; FOR ANTITUMOR/ANTICARCINOGENIC AGENTS; DIAGNOSIS AND THERAPY OF RELATED DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 1999-08-31 | — | — | US | disclosed |
| WO-1998049348-A1 | OLIGONUCLEOTIDES FOR ENHANCED BIOAVAILABILITY | ISIS PHARMACEUTICALS, INC. (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, SNRPE, DDX21 | TYMP 358/4885P2RY6 4710/4885ALDH1A1 4193/4885 |
| US-12121531-B2 | TREM compositions and uses thereof | TRMT1, TARBP1, TRMT1L | TYMP 28/4885P2RY6 713/4885ALDH1A1 4489/4885 |
| US-20250000890-A1 | TREM COMPOSITIONS AND USES THEREOF | TRMT1, TARBP1, TRMT1L | TYMP 28/4885P2RY6 713/4885ALDH1A1 4489/4885 |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, DDX21, SNRPE | TYMP 671/4885P2RY6 4754/4885ALDH1A1 4159/4885 |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | EFTUD2, DDX21, SNRPE | TYMP 671/4885P2RY6 4754/4885ALDH1A1 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.